A pan-variant SARS-CoV-2 vaccine composed of a mixture of conserved “asymptomatic” CD4+ and CD8+ T cell epitopes provides robust protection against infection and disease caused by six SARS-CoV-2 variants of concern. Here, CD4 is linked to infection.